Feb 22, 2017
This has certainly been an eventful few months for Immunomedics and its largest shareholder, venBio. In case you haven’t been following, below is a brief replay: Towards the end of last year, venBio, the beneficial owner of approximately 9.9% of the outstanding...
Feb 15, 2017
It has happened. After years of blood, sweat, and tears, the lead compound has made it to Phase 3 pivotal studies. Patients, physicians, the company team and investors all wait patiently for recruitment to complete and data to be collected, hoping to improve patient...
Feb 9, 2017
Often we are asked when is the best time to sell a medical device company to maximize valuation and return to investors. There is no correct answer, however there are multiple inflection points one can look at and management can weigh options based on monies raised...
Feb 2, 2017
Each quarter we compile key statistics and trends on strategic transactions and financing. Our 2016 year-end report now includes highlights from the US, Japanese and European markets as well as biopharma and medtech sectors. Click here to download your free...
